Spinal cord glioma
MONDO:0002542A neoplasm that arises from glial cells in the spinal cord. Representative examples include astrocytoma, oligodendroglioma, and ependymoma.
Also known as: glial neoplasm spinal cord, glial tumor of spinal cord, glial tumour of spinal cord, malignant glioma of spinal cord, spinal cord glial neoplasm, spinal cord glial tumor, spinal cord glial tumour, spinal cord glioma
2836 clinical trials for this condition and its sub-types, 3 tagged with Spinal cord glioma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Spinal cord glioma
-
Adult spinal cord glioblastoma 0 trials
-
Ependymal tumor of spinal cord 0 trials
1 sub-type
- Spinal cord ependymoma 0 trials Sub-types →
-
Spinal cord astrocytoma 0 trials
-
Spinal cord oligodendroglioma 0 trials
Most studied deeper sub-types
-
New hope for young brain cancer patients: targeted drug combo enters phase 2 trial
Disease control Recruiting nowThis study tests whether adding the drug olutasidenib to standard chemotherapy (temozolomide) can help children and young adults with a specific type of brain cancer (IDH1-mutant high-grade glioma) live longer. About 60 participants will receive the combination as maintenance the…
Phase 2 • Sponsor: Rigel Pharmaceuticals • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New hope for kids with deadly brain cancer? drug ONC206 enters human trials
Disease control Recruiting nowThis early-phase trial tests a new drug called ONC206 in children and young adults with diffuse midline glioma or other recurrent brain tumors. The drug aims to kill cancer cells by causing stress in them, without harming healthy cells. Researchers are looking for the safest dose…
Phase 1 • Sponsor: Sabine Mueller, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Immune cells take on deadly childhood brain cancer
Disease control Recruiting nowThis early-stage trial tests whether a new immune cell therapy called GD2 CAR T cells can be safely made and given to children and adults with a rare, aggressive brain tumor called H3K27M-mutant diffuse midline glioma. The study aims to find the right dose and check for side effe…
Phase 1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC